Hepato-Protective & Liver Care

Cyproheptadine Hydrochloride Tablets (4mg) and Syrup (2mg/5ml; alone or with Tricholine Citrate) is a first-generation piperidine antihistamine and potent serotonin 5-HT2 receptor antagonist on the WHO Model List framework. By blocking 5-HT2 serotonergic receptors in the ventromedial satiety center of the hypothalamus, it stimulates appetite and increases caloric intake and body weight. Concurrently, it blocks peripheral H1 histamine receptors and muscarinic receptors. Indicated for appetite stimulation in underweight or failure-to-thrive patients, allergic rhinitis, and urticaria.

Ursodeoxycholic Acid (UDCA) Tablets (150mg, 300mg) is a naturally occurring hydrophilic tertiary bile acid on the WHO Model List of Essential Medicines. It replaces toxic hydrophobic endogenous bile acids (cholic and chenodeoxycholic acids) in the circulating bile acid pool, protects cholangiocytes against bile acid-induced apoptosis, stimulates hepatobiliary secretion, and solubilizes cholesterol from gallstones by dispersing cholesterol in liquid crystals. Indicated for dissolution of radiolucent, non-calcified cholesterol gallstones (<15mm diameter) in functioning gallbladders, primary biliary cholangitis (PBC), and intrahepatic cholestasis of pregnancy (IHCP).

Sorbitol (7.15g) and Tricholine Citrate (550mg per 10ml) Solution is a dual-action osmotic laxative and lipotropic liver support tonic. Sorbitol exerts an osmotic gradient in the intestinal lumen that softens stool and promotes peristalsis, while also stimulating cholecystokinin release. Tricholine citrate acts as a choline donor that promotes phospholipid synthesis, facilitates fat mobilization from hepatocytes, and stimulates bile secretion. Indicated for occasional constipation, hepatic steatosis (fatty liver), and dyspepsia associated with sluggish hepatobiliary function.

Sofosbuvir Tablets (400mg) is a nucleotide analogue direct-acting antiviral on the WHO Model List of Essential Medicines. In hepatocytes, it is converted into active triphosphate GS-461203, which acts as a defective substrate for HCV NS5B RNA-dependent RNA polymerase, causing viral chain termination. Indicated in combination with other antiviral agents (daclatasvir, velpatasvir, or ribavirin) for the treatment of chronic hepatitis C across genotypes 1, 2, 3, 4, 5, and 6.

Entecavir Tablets (0.5mg) is a potent guanosine nucleoside reverse transcriptase inhibitor on the WHO Model List of Essential Medicines for chronic hepatitis B virus (HBV) infection. Following intracellular phosphorylation to active entecavir triphosphate, it competitively inhibits all three activities of HBV DNA polymerase: base priming, reverse transcription of negative-strand DNA from pregenomic RNA, and synthesis of positive-strand HBV DNA. Indicated for the treatment of chronic HBV infection in adults with evidence of active viral replication and liver inflammation.

Lecithin Soft Gel Capsules (1000mg) is an oral source of essential phospholipids, primarily phosphatidylcholine. Phosphatidylcholine is a structural component of cellular and canalicular membranes and an emulsifier in bile that prevents cholesterol precipitation into gallstones and aids hepatic lipid transport. Indicated for supportive therapy in fatty liver disease, hypercholesterolemia, and impaired fat digestion.

Metadoxine (500mg), Silymarin (140mg), and L-Ornithine L-Aspartate (150mg) Tablets is a hepatoprotective formulation. Silymarin (milk thistle flavonolignan) stabilizes hepatocyte plasma membranes, inhibits lipid peroxidation, and stimulates ribosomal RNA synthesis to accelerate liver regeneration. Metadoxine accelerates ethanol and acetaldehyde clearance, restoring cellular ATP and glutathione. LOLA enhances ammonia detoxification via the hepatic urea cycle. Indicated for alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD/NASH), acute and chronic hepatitis, and early liver cirrhosis.

L-Ornithine L-Aspartate (150mg) and Pancreatin (100mg) Tablets combines an ammonia-detoxifying metabolic amino acid with digestive pancreatic enzymes. LOLA stimulates urea cycle carbamoyl phosphate synthetase in hepatocytes and glutamine synthesis in skeletal muscle, clearing neurotoxic ammonia. Pancreatin supplies amylase, lipase, and protease to assist nutrient breakdown in patients with compromised digestion. Indicated for hepatic dysfunction, fatty liver, subclinical hepatic encephalopathy, and digestive insufficiency associated with liver cirrhosis.

Ursodeoxycholic Acid (UDCA) Tablets (150mg, 300mg) is a naturally occurring hydrophilic tertiary bile acid on the WHO Model List of Essential Medicines. It replaces toxic hydrophobic endogenous bile acids (cholic and chenodeoxycholic acids) in the circulating bile acid pool, protects cholangiocytes against bile acid-induced apoptosis, stimulates hepatobiliary secretion, and solubilizes cholesterol from gallstones by dispersing cholesterol in liquid crystals. Indicated for dissolution of radiolucent, non-calcified cholesterol gallstones (<15mm diameter) in functioning gallbladders, primary biliary cholangitis (PBC), and intrahepatic cholestasis of pregnancy (IHCP).

Silymarin Tablets (140mg) is a purified extract of flavonolignans (primarily silybin) from milk thistle (Silybum marianum) on the PMBI formulary. It acts as a potent antioxidant, scavenges reactive oxygen species, prevents lipid peroxidation of cell membranes, stimulates nucleolar polymerase A to enhance ribosomal protein synthesis, and exerts antifibrotic effects by suppressing hepatic stellate cell activation. Indicated as supportive therapy in chronic inflammatory liver disease, non-alcoholic fatty liver disease (NAFLD), and toxin/alcohol-induced liver injury.

Daclatasvir Tablets (60mg) is a direct-acting antiviral on the WHO Model List of Essential Medicines that specifically targets the hepatitis C virus NS5A protein. Inhibits both viral RNA replication and virion assembly. Indicated in combination with sofosbuvir (with or without ribavirin) for the treatment of chronic HCV genotypes 1 and 3.

Sofosbuvir (400mg) and Velpatasvir (100mg) Tablets is a fixed-dose, pan-genotypic direct-acting antiviral (DAA) regimen on the WHO Model List of Essential Medicines. Sofosbuvir is a nucleotide prodrug that inhibits HCV NS5B RNA-dependent RNA polymerase, causing chain termination. Velpatasvir is a potent inhibitor of HCV NS5A protein, preventing viral RNA replication and virion assembly. Achieves >95-98% sustained virologic response (SVR12/cure) across all HCV genotypes (1 through 6). Indicated for the treatment of adult and pediatric patients with chronic hepatitis C virus (HCV) infection with or without compensated cirrhosis, and with ribavirin for decompensated cirrhosis.

L-Ornithine L-Aspartate (150mg) and Pancreatin (100mg) Tablets combines an ammonia-detoxifying metabolic amino acid with digestive pancreatic enzymes. LOLA stimulates urea cycle carbamoyl phosphate synthetase in hepatocytes and glutamine synthesis in skeletal muscle, clearing neurotoxic ammonia. Pancreatin supplies amylase, lipase, and protease to assist nutrient breakdown in patients with compromised digestion. Indicated for hepatic dysfunction, fatty liver, subclinical hepatic encephalopathy, and digestive insufficiency associated with liver cirrhosis.

Papaya Leaf Extract Tablets (1100mg) is an oral herbal therapeutic derived from Carica papaya leaf extract on the PMBI formulary. Rich in active flavonoids, carpaine alkaloids, and enzymes (papain, chymopapain), it upregulates the ALOX12 (arachidonate 12-lipoxygenase) and CD110 (thrombopoietin receptor) genes in bone marrow megakaryocytes, stimulating platelet production. Concurrently, its proteolytic enzymes aid protein digestion and promote healthy gastrointestinal function. Indicated as supportive therapy for thrombocytopenia associated with dengue fever and other viral illnesses, and digestive weakness.

Ribavirin Capsules (200mg) is a synthetic guanosine nucleoside analogue antiviral on the WHO Model List of Essential Medicines. It inhibits inosine monophosphate dehydrogenase (IMPDH), depleting intracellular GTP pools and accelerating viral mutagenesis. Indicated in combination with direct-acting antivirals (e.g. sofosbuvir) for chronic hepatitis C in patients with decompensated cirrhosis or prior treatment failure.

Tenofovir Alafenamide (TAF) Tablets (25mg) is a targeted prodrug of the nucleotide reverse transcriptase inhibitor tenofovir on the WHO Model List of Essential Medicines. TAF enters hepatocytes through passive diffusion and hepatic OATP1B1/1B3 transporters and is intracellularly hydrolyzed by carboxylesterase 1 (CES1) to tenofovir. This delivers high intracellular antiviral concentrations with over 90% lower systemic plasma tenofovir exposure compared to tenofovir disoproxil fumarate (TDF), dramatically reducing renal tubulopathy and bone mineral density loss. Indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and adolescents with compensated liver disease.

Obeticholic Acid Tablets (5mg, 10mg) is a synthetic modified bile acid and highly selective, potent farnesoid X receptor (FXR) agonist on the PMBI formulary. FXR is a nuclear receptor expressed in the liver and intestine that regulates bile acid synthesis, inflammation, and fibrosis. Activation of FXR suppresses bile acid synthesis by downregulating CYP7A1, promotes biliary secretion, and reduces hepatic exposure to toxic bile acids. Indicated for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients intolerant to UDCA.

Obeticholic Acid Tablets (5mg, 10mg) is a synthetic modified bile acid and highly selective, potent farnesoid X receptor (FXR) agonist on the PMBI formulary. FXR is a nuclear receptor expressed in the liver and intestine that regulates bile acid synthesis, inflammation, and fibrosis. Activation of FXR suppresses bile acid synthesis by downregulating CYP7A1, promotes biliary secretion, and reduces hepatic exposure to toxic bile acids. Indicated for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients intolerant to UDCA.

S-Adenosyl L-Methionine (SAMe) Tablets (200mg, 400mg) is an enteric-coated biological sulfonium compound and primary biological methyl donor on the PMBI formulary. It is a vital precursor in transmethylation, transsulfuration (generating glutathione, taurine, and sulfate), and polyamine pathways in hepatocytes. In cholestasis, SAMe restores hepatocyte membrane fluidity by methylating phospholipids and enhances glutathione-mediated detoxification. Indicated for intrahepatic cholestasis in pre-cirrhotic and cirrhotic states, intrahepatic cholestasis of pregnancy (IHCP), and alcoholic/toxic liver disease.

S-Adenosyl L-Methionine (SAMe) Tablets (200mg, 400mg) is an enteric-coated biological sulfonium compound and primary biological methyl donor on the PMBI formulary. It is a vital precursor in transmethylation, transsulfuration (generating glutathione, taurine, and sulfate), and polyamine pathways in hepatocytes. In cholestasis, SAMe restores hepatocyte membrane fluidity by methylating phospholipids and enhances glutathione-mediated detoxification. Indicated for intrahepatic cholestasis in pre-cirrhotic and cirrhotic states, intrahepatic cholestasis of pregnancy (IHCP), and alcoholic/toxic liver disease.

Trientine Hydrochloride Capsules (250mg) is an oral copper-chelating agent on the WHO Model List of Essential Medicines. It binds copper by forming a stable, non-toxic planar tetradentate ring complex that is excreted in the urine, removing excess systemic and hepatic copper accumulation. Indicated for the treatment of Wilson's disease in patients who are intolerant of or unable to take penicillamine (due to severe adverse reactions or lupus-like syndromes).

Lamivudine Tablets (100mg) is a synthetic cytosine nucleoside analogue reverse transcriptase inhibitor on the WHO Model List of Essential Medicines. Intracellular lamivudine triphosphate incorporates into viral DNA, competitively inhibiting HBV DNA polymerase and causing DNA chain termination. Indicated for the treatment of chronic hepatitis B infection in patients with evidence of hepatitis B viral replication and active liver inflammation.